2 Beaten-Down Medical Device Stocks to Buy for a 2022 Rebound

NYSE: MDT | Medtronic PLC News, Ratings, and Charts

MDT – The medical devices industry witnessed a solid recovery last year. And this trend will likely continue, driven by rising demand for non-emergency medical procedures and rapid tech integration. Thus, we think buying the dip in quality medical devices stocks Medtronic (MDT) and Zimmer Biomet (ZBH) could deliver handsome returns this year. Read on.

Increased capital investments and rapid technology integration aided the medical devices industry’s recovery last year. Furthermore, the rising prevalence of chronic diseases, and an emphasis on early diagnosis and treatment, are facilitating the industry’s rebound.

The adoption of advanced technologies such as artificial intelligence (AI), 3D printing, and the development of other smart gadgets are positioning the industry for long-term growth. The global medical device market is expected to reach $657.98 billion by 2028, registering a CAGR of 5.4%.

Prominent medical devices companies Medtronic plc (MDT) and Zimmer Biomet Holdings Inc. (ZBH) have witnessed significant price declines over the past few months. However, based on their solid fundamentals, we think they could gain considerably in the near term.

Medtronic plc (MDT)

MDT develops, produces, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company operates through four segments: Cardiovascular Portfolio; Neuroscience Portfolio; Medical-Surgical Portfolio; and Diabetes Operating Unit.

Last month, the U.S. Food and Drug Administration (FDA) awarded 510(k) approval for MDT’s INVOSTM 7100 cerebral/somatic oximetry device for children aged upto 18 years. The INVOS system detects vital signals to help pediatric doctors make time-critical choices about hemodynamic management, ventilation, and resuscitation for premature infants, neonates, children, and other patients.

For the second quarter ended October 29, 2021, MDT’s net sales increased 2.6% from the year-ago value to $7.85 billion. Its operating income grew 68.1% year-over-year to $1.56 billion. Its net income surged 168.1% from the year-ago value to $1.31 billion, while its EPS increased 169.4% from the prior-year quarter to $0.97.

The consensus EPS estimate of $5.69 for fiscal 2022 represents a 28.2% increase year-over-year. The revenue is expected to increase 5.3% in fiscal 2023. The stock has declined 17.5% over the past three months and 3.1% over the past month.

It is no surprise that MDT has an overall B rating, which equates to Buy in our POWR Ratings system. The POWR Ratings are calculated considering 118 different factors, with each factor weighted to an optimal degree. The stock also has a B grade for Growth, Value, and Stability. In the Medical – Devices & Equipment industry, MDT is ranked #17 of 169 stocks.

Beyond the POWR Ratings grades I have just highlighted, you can view the MDT ratings for Sentiment, Quality, and Momentum.

Zimmer Biomet Holdings Inc. (ZBH)

ZBH and its subsidiaries research, manufacture, and sell musculoskeletal healthcare products and solutions internationally. The company’s products and solutions are used to treat patients who have bone, joint, or supporting soft tissue illnesses or injuries. It caters to orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other professionals.

ZBH’s revenue came in at $1.92 billion for the third quarter ended September 30, 2021. The company reported an operating income of $214.9 million, while its net income came in at $145.8 million for this period. Its EPS amounted to $0.69 over this period.

The company’s EPS is expected to grow 30.5% year-over-year to $7.4 in fiscal 2021. Analysts expect ZBH’s revenue to increase 12% year-over-year to $7.87 billion in fiscal 2021. Although the stock has declined 21% over the past six months, it has gained 6.2% over the past month.

ZBH’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which equates to Buy in our POWR Ratings system. ZBH also has a B grade for Value. The stock is ranked #38 in the same industry.

Beyond the POWR Ratings grades I have just highlighted, you can see the ZBH ratings for Growth, Quality, Sentiment, Stability, and Momentum.


MDT shares were trading at $106.60 per share on Tuesday afternoon, up $0.50 (+0.47%). Year-to-date, MDT has gained 3.04%, versus a 0.62% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MDTGet RatingGet RatingGet Rating
ZBHGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

How to Beat the Market the Rest of the Year?

The easy gains that came at the start of this new bull market are fading away fast. In fact the stock market (SPY) has become quite volatile with 2022 starting off with a nasty correction. Gladly there are easy solutions as will be shared in this commentary to get you on the right path to outperform the market the rest of the year. Read the rest below...

:  |  News, Ratings, and Charts

3 Stocks that Are Thriving in an Inflationary Environment

Inflation is one of the biggest threats facing the economy. One profitable strategy during this period of high inflation is to focus on stocks that have pricing power, as these companies’ margins will continue to expand. In contrast, stocks without pricing power are likely to underperform as margin compression erodes EPS. Therefore, investors should consider buying these 3 stocks that are thriving in this inflationary environment: Olin (OLN), Nucor (NUE), and Chemours (CC).

:  |  News, Ratings, and Charts

Stock Market “Nausea Index” Going Off

The stock market (SPY) has seen fresh lows this week scaring many investors into selling their positions. On the other hand, 40 year investment veteran shares a proprietary market indicator that points to a significant bounce coming soon. Is he right? You be the judge by reading below.

:  |  News, Ratings, and Charts

4 Best Value Stocks to Buy in January

In times of high inflation, value stocks tend to outperform growth stocks and have done so over the past year. Amid the rising inflationary pressure and looming interest rate hikes, fundamentally sound value stocks ArcelorMittal (MT), Covestro (COVTY), KT Corporation (KT), and Nature’s Sunshine (NATR) could be solid bets.

:  |  News, Ratings, and Charts

Stock Market “Nausea Index” Going Off

The stock market (SPY) has seen fresh lows this week scaring many investors into selling their positions. On the other hand, 40 year investment veteran shares a proprietary market indicator that points to a significant bounce coming soon. Is he right? You be the judge by reading below.

Read More Stories

More Medtronic PLC (MDT) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MDT News